Study on the Prediction of Regional Lymph Node Metastasis in Colorectal Cancer by Spectral CT Combined With MSI

Spectral CT was used to prospectively collect medical images and clinical data related to colorectal cancer, evaluate the effect of image quality in the diagnosis of colorectal cancer, and evaluate the application value in the accurate staging of colorectal cancer, so as to provide a more accurate clinical basis for diagnosis, promote the development of individualized treatment, and ultimately improve the prognosis of patients.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Conditions

Colo-rectal Cancer Colonic Diseases Colonic Neoplasms Colorectal Neoplasms Digestive System Diseases Digestive System Neoplasms Gastrointestinal Diseases Gastrointestinal Neoplasms Intestinal Diseases Intestinal Neoplasms Neoplasms Neoplasms by Site

Age range

18 year–90 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Yunnan Cancer Hospital

Kunming, Yunnan, 650000, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

(1) Undergo contrast-enhanced Quark energy spectral CT examination of the lower abdomen/pelvis within 1 week before treatment;(2) MSI status confirmed;(3) Age >18 years;(4) Patients with suspected colorectal cancer;(5) Patients who provided informed consent.

Exclusion criteria

(1) Severe cardiac, pulmonary, or renal insufficiency;(2) Allergy to iodine-based contrast agents;(3) Inability to cooperate during the CT examination;(5) Poor image quality from Quark spectral CT scans;(6) Pregnant or lactating women.

Treatment and study plan

Investigating the role of spectral CT combined with MSI status in the diagnosis and treatment of colorectal cancer lymph nodes.

Diagnostic Test

The CT scan is part of the standard treatment protocol.

Primary outcomes

Pathological TNM staging

Time frame: 1 day

Pathological examination information: The pathology results using surgery/biopsy data are the gold standard, and the depth of tumor invasion, lymph node metastasis, and distant metastasis are recorded

Sponsors and collaborators

Lead sponsor

Yunnan Cancer Hospital

Other

Registry information

Important dates

Study start: 2025
Primary completion: 2026
Study completion: 2026
First posted: May 4, 2026
Registry last updated: May 4, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Active, Not Recruiting